Pfizer to Launch Two Oncology Biosimilars at Lowest Wholesale Acquisition Cost in the US

 Pfizer to Launch Two Oncology Biosimilars at Lowest Wholesale Acquisition Cost in the US

Pfizer to Launch Two Oncology Biosimilars at Lowest Wholesale Acquisition Cost in the US

Shots:

  • Pfizer anticipates the launch of two oncology biosimilars, Ruxience (biosimilar, rituximab) & Trazimera (biosimilar, trastuzumab) at lowest WAC among all the biosimilars present in the market
  • Pfizer will launch Ruxience today at WAC of $71.68/10mg or 24% discount to the WAC of Rituxan while Trazimera at WAC of $80.74/10 mg or 22% discount to the WAC of Herceptin. Zirabev was launched on Dec 31, 2019 at $61.34/10mg or 23% discount to the WAC of Avastin
  • Ruxience referencing Roche’s Rituxan, available for NHL, CLL, GPA and MPA while Trazimera referencing Roche’s Herceptin, indicated for the treatment of HER2+ BC and HER2 overexpressing GE. Zirabev referencing Roche’s Avastin and is available to treat multiple cancer indications

Click here to­ read full press release/ article | Ref: Pfizer | Image: Pfizer

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post